Global /Taiwan /Healthcare /Drug Manufacturers - General /MENS

Jyong Biotech Ltd.

MENS

• NASDAQ: MENS • Delayed

2.20USD 1.4%

As of 5 June 2026, Jyong Biotech Ltd. has a market cap of $169.18M USD, ranking #22120 globally and #1055 in Taiwan. It ranks #1997 in the Healthcare sector, and #721 in the Drug Manufacturers - General industry.

Global Rank

22120

Country Rank

1055

Sector Rank

1997

Industry Rank

721

Key Stats

Market Cap

$169.18MUSD

Enterprise Value

$185.52MUSD

EBITDA (TTM)

-$1.8MUSD

Net Income (TTM)

-$2.95MUSD

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Fu-Feng Kuo open_in_new

Founded

2002

IPO

17 Jun 2025

Website

jyongbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.4%	3.5%	14%	-13%	-95%	-44%	-86%	-86%	-86%

News

MENS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	MENS Jyong Biotech Ltd ISIN: KYG831161065 Shares Out.: Shares Outstanding: 74.234M¹ Shares Float: 28.058M² TV: TradingView: NASDAQ: MENS SA: Stock Analysis: NASDAQ: MENS YF: Yahoo Finance: MENS GF: Google Finance: NASDAQ: MENS NQ: NASDAQ: MENS BA: Barron's: MENS MS: Morningstar: XNAS: MENS	2.20 USD	TV: TradingView: NASDAQ: MENS SA: Stock Analysis: NASDAQ: MENS YF: Yahoo Finance: MENS GF: Google Finance: NASDAQ: MENS NQ: NASDAQ: MENS BA: Barron's: MENS MS: Morningstar: XNAS: MENS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jyong Biotech Ltd.

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.8B 245.34B TWD 5K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.84B 57.95B TWD 989%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$925.55M 29.11B TWD 447%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$809.3M 25.46B TWD 378%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$789.12M 24.82B TWD 366%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$584.14M 18.38B TWD 245%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 450K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 323K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 213K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 191K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 171K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 163K%	20.5	Switzerland

chevron_leftBack